Life expectancy of more than 100 years could soon become common thanks to advances in technology, a report suggests.
The Bank of America report predicts that death-delaying technologies will be one of the biggest investment areas over the next decade.
The market is already worth £85bn ($110bn), a value that the investment bank expects to rise to around £462bn ($600bn) by 2025.
Merrill Lynch analysts Felix Tran and Haim Israel, who wrote the report, said medical knowledge will double every 73 days by 2020, versus every 3.5 years in 2010.
“Genomic sequencing costs have fallen 99.999% since 2003,” they added. “This has enabled a new frontier in precision medicine to further extend life expectancy, heralding a ‘techmanity’ – technology meets humanity – revolution.”
The quest to put off death, dubbed “ammortality”, is expected to be a massive market by 2025, one with potential to be worth around £388bn ($504bn), according to the study reported in the Daily Mail.
The authors said ammortality will help to improve health spans and lifespans to the betterment of human vitality, enabling the world population to live freer of disease.
Another growing market is the field of genomics, one that is projected to become around a £32bn ($41bn) industry by 2025 and includes the investigation and editing of the human genome.
In addition, companies offering revolutionary healthcare solutions to treat challenging diseases such as Alzheimer’s, cystic fibrosis and Parkinson’s will remain popular investment opportunities.
The application of artificial intelligence and big data techniques to healthcare is expected to be of increasing use to researchers studying the causes and effects of diseases. The authors said developments in this area have the potential to lower health-related costs while enhancing precision medicine techniques.